Merck has acquired the chromatography business of JSR Life Sciences, enhancing its bioprocessing portfolio with Amsphere Protein A resins. This acquisition strengthens Merck's capabilities in monoclonal antibody manufacturing by improving Protein A capture efficiency, which is essential for productivity and scaling. The deal involves over 50 personnel from Belgium, bringing valuable expertise to Merck's Process Solutions business. This strategic move aims to address customer demands for faster, more efficient biologics production, aiming to enhance process consistency and accelerate access to critical therapies.
